- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic severe atopic dermatitis
- Meeting Date: July 2022
- Public Summary Document (PSD) July 2022 PBAC Meeting - (PDF 521KB)
- Public Summary Document (PSD) July 2022 PBAC Meeting - (Word 126KB)
Dupilumab – July 2022
Dupilumab: Injection 200 mg in 1.14 mL single dose pre-filled syringe, Injection 300 mg in 2 mL single dose pre-filled syringe; Dupixent®
Last updated
11 November 2022